Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development
- PMID: 36305711
- DOI: 10.1042/BCJ20210233
Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development
Abstract
Through activation of immune cells, the immune system is responsible for identifying and destroying infected or otherwise damaged cells including tumorigenic cells that can be recognized as foreign, thus maintaining homeostasis. However, tumor cells have evolved several mechanisms to avoid immune cell detection and killing, resulting in tumor growth and progression. In the tumor microenvironment, tumor infiltrating immune cells are inactivated by soluble factors or tumor promoting conditions and lose their effects on tumor cells. Analysis of signaling and crosstalk between immune cells and tumor cells have helped us to understand in more detail the mechanisms of tumor immune evasion and this forms basis for drug development strategies in the area of cancer immunotherapy. In this review, we will summarize the dominant signaling networks involved in immune escape and describe the status of development of therapeutic strategies to target tumor immune evasion mechanisms with focus on how the tumor microenvironment interacts with T cells.
Keywords: adenosine; immune checkpoints; immune evasion; immunotherapy; lipid mediators; signal networks.
© 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
Similar articles
-
Role of m6A modifications in immune evasion and immunotherapy.Med Oncol. 2024 May 18;41(6):159. doi: 10.1007/s12032-024-02402-9. Med Oncol. 2024. PMID: 38761335 Review.
-
Mitochondrial transfer drives immune evasion in tumor microenvironment.Trends Cancer. 2025 May;11(5):424-426. doi: 10.1016/j.trecan.2025.04.002. Epub 2025 Apr 22. Trends Cancer. 2025. PMID: 40268608
-
Cracking the Codes behind Cancer Cells' Immune Evasion.Int J Mol Sci. 2024 Aug 15;25(16):8899. doi: 10.3390/ijms25168899. Int J Mol Sci. 2024. PMID: 39201585 Free PMC article. Review.
-
Mechanisms of immune escape in the cancer immune cycle.Int Immunopharmacol. 2020 Sep;86:106700. doi: 10.1016/j.intimp.2020.106700. Epub 2020 Jun 23. Int Immunopharmacol. 2020. PMID: 32590316 Review.
-
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.Cancer Lett. 2020 Jan 1;468:72-81. doi: 10.1016/j.canlet.2019.10.013. Epub 2019 Oct 9. Cancer Lett. 2020. PMID: 31605776 Review.
Cited by
-
Epigenetics and Metabolism Reprogramming Interplay into Glioblastoma: Novel Insights on Immunosuppressive Mechanisms.Antioxidants (Basel). 2023 Jan 18;12(2):220. doi: 10.3390/antiox12020220. Antioxidants (Basel). 2023. PMID: 36829778 Free PMC article. Review.
-
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives.Pharmaceutics. 2023 Apr 4;15(4):1143. doi: 10.3390/pharmaceutics15041143. Pharmaceutics. 2023. PMID: 37111629 Free PMC article. Review.
-
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma.Cancers (Basel). 2023 Jan 20;15(3):654. doi: 10.3390/cancers15030654. Cancers (Basel). 2023. PMID: 36765612 Free PMC article. Review.
-
Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies.Med Oncol. 2025 Mar 18;42(4):117. doi: 10.1007/s12032-025-02641-4. Med Oncol. 2025. PMID: 40102282 Review.
-
Integrative pan-cancer analysis reveals the prognostic and immunotherapeutic value of ALKBH7 in HNSC.Aging (Albany NY). 2024 Jun 29;16(19):12781-12805. doi: 10.18632/aging.205981. Epub 2024 Jun 29. Aging (Albany NY). 2024. PMID: 39400540 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical